| Drug Class |
Anti-platelet agent |
| Mechanism |
Irreversibly to the platelet P2Y12 receptor, inhibiting ADP-mediated platelet activation and aggregation |
| Typical Dose |
75mg OD or 300mg loading dose |
| Indications |
- Secondary prevention of atherosclerotic events
- Prior to PCI to prevent atherothrombotic events
|
| Contra-indications |
- Active bleeding
- Breast feeding
|
| Side-effects |
- Dyspepsia
- Abdo pain
- Diarrhoea
- Bleeding disorders
|
| Interactions |
NSAIDs - increased risk of haemorrhage |
| Elimination |
50% urine 50% faeces |
| Additional Notes |
|
ALPHA